NeuroSigma - About the company
NeuroSigma is a seed company based in Los Angeles (United States), founded in 2008 by Leon Ekchian. It operates as a Develops and commercializes trigeminal nerve stimulation (TNS) devices for treatment of psychiatric disorders. NeuroSigma has raised $2.92M in funding. The company has 219 active competitors, including 61 funded and 7 that have exited. Its top competitors include companies like Muse, Apollo Neuroscience and Flow Neuroscience.
Company Details
NeuroSigma, Inc. is a medical device company focused on commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD). NeuroSigma is actively engaged in preclinical research and development, as well as groundbreaking Phase I, II, & III clinical trials.
- Website
- www.neurosigma.com/
Key Metrics
Founded Year
2008
Location
Los Angeles, United States
Stage
Seed
Total Funding
$2.92M in 14 rounds
Latest Funding Round
Investors
Ranked
10th among 219 active competitors
Employee Count
11 as on Aug 31, 2026
Legal entities associated with NeuroSigma
NeuroSigma is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Neurosigma, Inc. CIN: 1494756 , United States, Active | Aug 25, 2019 | - | 8 (As on Dec 31, 2019) | - |
Sign up to download NeuroSigma's company profile
NeuroSigma's funding and investors
NeuroSigma has raised a total funding of $2.92M over 14 rounds. Its first funding round was on Jun 08, 2010. Its latest funding round was a Post IPO round on Dec 08, 2021 for $*****. 1 investor participated in its latest round. NeuroSigma has 4 institutional investors.
Here is the list of recent funding rounds of NeuroSigma:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 08, 2021 | 5260671 | Post IPO | 2703369 | 2022175 | 7200049 | 9848942 |
Sep 21, 2020 | 9227676 | Post IPO | 4463397 | 2086014 | 1833444 | |
Sep 20, 2018 | 8068204 | Grant (prize money) | 5598074 | 5988273 | 8392389 |
View details of NeuroSigma's funding rounds and investors
NeuroSigma's founders and board of directors
Founder? Claim ProfileThe founders of NeuroSigma is Leon Ekchian. Leon Ekchian is the CEO of NeuroSigma.
Here are the details of NeuroSigma's key team members:
- Leon Ekchian: Co-Founder & CEO of NeuroSigma. Contact Info: 1 email address
View details of NeuroSigma's Founder profiles and Board Members
NeuroSigma's employee count trend
NeuroSigma has 11 employees as of Aug 26. Here is NeuroSigma's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
NeuroSigma's Competitors and alternates
Top competitors of NeuroSigma include Muse, Apollo Neuroscience and Flow Neuroscience. Here is the list of Top 10 competitors of NeuroSigma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Provider of brainwave tracking devices and related premium subscription services | $57.4M | 63/100 | ||
2nd | Apollo Neuroscience 2017, Pittsburgh (United States), Series A | Developer of wearable technology for stress reduction, sleep improvement, and performance enhancement | $30.7M | 62/100 | |
3rd | Flow Neuroscience 2016, Malmo (Sweden), Series A | Provider of a wearable device for stress and anxiety management | $11.9M | 61/100 | |
4th | Freespira 2008, Danville (United States), Series D | Medical device & Mobile app to treat panic disorders | $48.9M | 60/100 | |
5th | Motif neurotech 2022, Houston (United States), Series A | Developer of minimally invasive bioelectronics for mental health disorders | $18.8M | 60/100 | |
6th | Hapbee 2004, Phoenix (United States), Public | Retailer of wearable technology products designed to improve sleep and wellness | $4.8M | 59/100 | |
7th | Mave Health 2023, Bengaluru (India), Seed | Provider of NIBS wearable device designed to improve brain health | $2.85M | 58/100 | |
8th | BrainCo 2015, Somerville (United States), Series A | Provider of a prosthetic hand and EEG headband for brain signal | $292M | 58/100 | |
9th | Cumulus Neuro 2015, Belfast (United Kingdom), Series A | AI and cloud-based brain physiology analysis tool for clinical trials | $19.6M | 57/100 | |
10th | NeuroSigma 2008, Los Angeles (United States), Seed | Develops and commercializes trigeminal nerve stimulation (TNS) devices for treatment of psychiatric disorders | $2.92M | 57/100 |
Looking for more details on NeuroSigma's competitors? Click here to see the top ones
NeuroSigma's Investments and acquisitions
NeuroSigma has made no investments or acquisitions yet.
Reports related to NeuroSigma
Here is the latest report on NeuroSigma's sector:
News related to NeuroSigma
Media has covered NeuroSigma for a total of 2 events in the last 1 year, 1 of them has been about company updates and 1 about partnerships.
•
Firefly Neuroscience and NeuroSigma Partner to Expand Access to FDA-Cleared Non-Drug Treatment for Pediatric ADHDGlobeNewswire•Sep 25, 2026•FireFly Neuroscience, NeuroSigma
•
NeuroSigma Invests $1M in High-Volume Manufacturing for Monarch eTNS DeviceGlobeNewswire•Dec 15, 2025•NeuroSigma
•
NeuroSigma Receives Notice of Allowance for Monarch eTNS System Patent in ChinaGlobeNewswire•Jun 10, 2025•NeuroSigma
•
NeuroSigma patents trigeminal nerve stimulation for dyslexia and other neurodevelopmental disorders.GlobeNewswire•Jan 22, 2025•NeuroSigma
•
NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHDBioSpace•Jan 18, 2024•NeuroSigma
•
Monarch eTNS System Approved by Singapore RegulatorsMedical Product Outsourcing•Dec 06, 2023•NeuroSigma
•
NeuroSigma Announces Strategic Digital Marketing Partnership with Data360GlobeNewswire•Jan 31, 2023•NeuroSigma, Data360
•
KT to invest $2 million in US voice biomarker developerKedglobal•Nov 10, 2022•KT, Sonde Health, Qualcomm, GN Group and 2 others
•
NeuroSigma Announces King’s College London Team Receives MHRA Approval to Commence Largest Clinical Trial of eTNS for Pediatric ADHD to DateGlobeNewswire•Apr 07, 2022•NeuroSigma
•
Are you a Founder ?
FAQs about NeuroSigma
Explore our recently published companies
- Marketing Agency - Deptford based, 2020 founded, Unfunded company
- Aquiyel Services - Houston based, 2020 founded, Public company
- B2clogin.com - 2017 founded, Unfunded company
- Compose Finance - Warsaw based, 2024 founded, Unfunded company
- Bubbls - United Kingdom based, Unfunded company
- TedhiMedhi Family - India based, Unfunded company